We evaluated two commercial human T-cell lymphotropic virus (HTLV) Western blot (WB; immunoblot) kits, Cambridge Biotech Corp. (CBC) and Diagnostic Biotechnology Ltd. (DBL). Both methods employ HTLV type I (HTLV-I) viral lysate and rgp2l. The DBL WB kit also distinguishes between HTLV-I and HTLV-II antibodies, using an HTLV-I-specific and an HTLV-II-specific recombinant. Fifty weakly reactive HTLV-IIpositive plasma specimens which were falsely negative with the Abbott enzyme immunoassay (EIA) and 50
It previously has been shown that human T-cell lymphotropic virus type I (HTLV-I) immunoblot (Western blot [WB])
antigens consisting of only viral lysate are not sensitive, especially for detection of antibody to HTLV-11 (2) . Although the addition of a recombinant transmembrane envelope protein, rgp2l, greatly improves the sensitivity of the WB for detection of both HTLV-I and HTLV-11 antibodies, nonspecific reactions with the recombinant protein, as well as with core proteins, also occur (6) .
In this study, we evaluated two commercial HTLV WB kits, both of which employ rgp2l and viral lysate. Fifty weakly reactive HTLV-II samples that were falsely negative by enzyme immunoassay (EIA) were selected to compare the sensitivities of the two kits. Because (4) .
WB. HTLV-1 viral lysate (Hillcrest Biologicals, Cypress, Calif.) spiked with recombinant gp2l from Hoffmann-LaRoche, Inc., Nutley, N.J., was used for the in-house test, as previously described (2) . A specimen was considered positive if it reacted with p19 or p24 and env.
The following two commercial blots were evaluated: HTLV-I WB kit from Cambridge Biotech Corp. (CBC), Worcester, Mass., which contains HTLV-I viral lysate and rgp2l; and Diagnostic Biotechnology Ltd. (DBL) 2.3 blot, from Genelabs Diagnostics (Pte) Ltd., Singapore, which employs HTLV-I viral lysate, rgp2l, a unique HTLV-I envelope recombinant protein (rgp46-1), and a unique HTLV-11 envelope recombinant protein (rgp46-II). The tests were performed and interpreted according to the manufacturers' directions.
RIPA. The specimens were reacted with HTLV-I (MT2) and HTLV-II (clone 19) RIPA antigen labeled with 3"S-methionine and 35S-cysteine, and the test was performed as previously described (2) . A specimen was considered positive if it reacted with either gp68 of the HTLV-I antigen or gp67 of the HTLV-II antigen. PCR. The PCR was performed as previously described (5) with primer pair SK110-SK111 and probes that were specific for HTLV-I (SK112) and HTLV-II (SK188). Primers and probes for HLA-DQa were also included to detect the presence of PCR inhibitors or lack of DNA.
RESULTS
A positive interpretation (for HTLV-I/II) with the CBC WB requires bands present at p24 and gp46 or rgp2l. An HTLV-I/II positive with the DBL WB is defined as reactivity with gag (p19 or p24) and env (gp46 or rgp2l). A specimen which reacts with p19 or p24 and rgp2l plus gp46 or rgp46-1 is typed as HTLV-I. An HTLV-II positive is defined as reactivity with p24, rgp2l, and rgp46-II. Thirty-two (64%) of the 50 weakly reactive HTLV-II-positive samples were correctly identified as positive by the CBC WB and typed as HTLV-II by the DBL WB. Table 2 displays the discrepant WB results: two samples were positive with the DBL WB but did not react with the HTLV-II typing recombinant, rgp46-II; five reacted with rgp46-I and were mistyped as HTLV-I; four were typed as dual infections; and seven were indeterminate. Five of these were also indeterminate with the CBC WB. Although these indeterminate samples reacted with the recombinant env proteins, they did not display the core bands required for a positive interpretation. Five of the seven samples with indeterminate results in one or both tests gave EIA ratios of 0.5 or less (Table 1) .
Only 22 (44%) of the 50 negative samples were negative by both commercial immunoblots. Eleven samples were interpreted as indeterminate by both methods, 13 were indeterminate by CBC but negative by DBL, 2 were negative by CBC but indeterminate by DBL, and 2 were indeterminate by CBC and positive by DBL (Table 3 ). The most prevalent nonspecific band with both methods was p19, followed by p24 and p28 for 256  64  32  256  1,024  512  128  32  64  256  256  512  64  64  256  1,024  256  256  64  64  64  256  64  64  256  256  16  256  64   II  II  II  II  II  II  II  II  II  II  II  II  II  II  II  II  II  II  II  II   II   II  II  II  II  II  II  II  II  II  II   II   II  II  II  II   II  II   II  II   II   II  II   II  II  II   II  II  II   II   VOL. 32, 1994 on September 30, 2017 by guest http://jcm.asm.org/ Downloaded from Specimen tioned, these specimens were typed as HTLV-II by IFA titration and PCR. In addition, one would expect HTLV-I positives to display a p19 core band rather than p24. It appears that the 11 reactions with the rgp46-I band shown in Table 2 are nonspecific. All samples reacted with rgp2l in both kits. However, although a p24 band could be demonstrated in all but one of these specimens with our in-house WB, the amount of p24 antigen in these commercial kits was insufficient to detect p24 antibody in five samples with CBC and in seven samples with DBL.
The apparent greater amount of p24 in the CBC antigen was a disadvantage when determining specificity with the 50 EIA false-positive specimens. Although the numbers of negative specimens reacting nonspecifically with p19 were comparable (11 versus 9) for the CBC and DBL kits, there were 11 false-positive p24 reactions with CBC versus only 2 with DBL. There were 24 negative interpretations with the CBC WB and 35 with the DBL kit, giving specificities of 48 and 70% for CBC and DBL, respectively. Differences in the manufacturers' recommendations for a positive reaction resulted in two falsepositive interpretations for DBL, although the WB reactions of these two samples were similar with both kits.
Specificities and sensitivities of the licensed EIA kits vary (1). One way to minimize indeterminate WB results with negative specimens is to choose the most specific as well as the most sensitive screening test available. As mentioned previously, all of these Ortho EIA-false-positive samples were negative with the Abbott EIA. It is not usually necessary to perform the WB on a specimen that is EIA negative.
The rgp2l protein is very sensitive. In the past 4 years, we have performed IFA titration, in-house WB, RIPA, and PCR on over 450 positive specimens. We have never experienced an HTLV-positive sample that did not react with rgp2l in our WB. Thus, we interpret rgp2l-negative reactions as WB negative, regardless of the presence of other bands, since rgp2l is the most sensitive antigen in our HTLV WB. We have found this to be a reliable method which greatly reduces the number of WB-indeterminate interpretations on negative samples.
In the present study, we chose 50 of our weakest HTLV-IIpositive specimens to compare the sensitivities of these two commercial WB kits. Both methods detected antibody to rgp2l in all 50 specimens. Thus, it might be assumed that if a sample did not react with rgp2l in these immunoblots, it could be interpreted as WB negative, regardless of reactions with other bands. This would improve the specificities of the CBC and DBL kits to 90 and 86%, respectively, without affecting the sensitivity.
